详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)

文献详情

资源类型：

作者：

机构： [1]Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou/China, [2]Guangdong General Hospital, Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, Guangzhou/China, [3]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai/China, [4]Medical Oncology, Jiangsu Cancer Hospital, Nanjing/China, [5]Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/China, [6]Department of Respiratory Medicine, Nanjing Military General Hospital, Nanjing/China, [7]Fujian Cancer Hospital, Fujian/China, [8]Wuhan Union Hospital, Wuhan/China, [9]Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun/China, [10]Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou/China, [11]Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha/China, [12]Harbin Medical University Cancer Hospital, Harbin/China, [13]Department of Respiratory Medicine, Peking Union Medical College Hosptial, Peking Union Medical College&chinese Academy of Medical Sciences, Beijing, China., Beijing/China, [14]Department of Pulmonary Oncology, 307 Hospital of the Academy of Military Medical Sciences, Cancer Center, Beijing/China, [15]Betta Pharmaceuticals Co.,ltd, Beijing/China, [16]Zhongshan Chenxinghai Hospital, Zhongshan/China

出处：

ISSN：

关键词： phase 3 trial WBI Brain metastasis EGFR TKI

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

第一作者：

第一作者机构： [1]Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou/China,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]STE029逆转肺腺癌EGFR-TKI耐药及其机制研究 [2]Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS) [3]Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study [4]Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer [5]Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial. [6]Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC. [7]Pharmacokinetics of Osimertinib (AZD9291) in Chinese Patients with Advanced NSCLC: A Phase I Study [8]Development of immunotherapy for brain metastasis (Review). [9]First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial [10]Potential applications of clickable probes in EGFR activity visualization and prediction of EGFR-TKI therapy response for NSCLC patients.